Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study

Novo Nordisk A/S

Summary

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Eligibility

Age range: 18–75 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion criteria * Male or female (sex at birth). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening. * Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline). Exclusion criteria * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for…

Interventions

Drug
NNC0662-0419
NNC0662-0419 will be administered subcutaneously.
Drug
Semaglutide
Semaglutide will be administered subcutaneously.
Drug
Placebo
Placebo will be administered subcutaneously.

Locations (63)

First Valley Medical Group
Lancaster, California
Torrance Clinical Research Institute, Inc.
Lomita, California
Ark Clinical Research
Long Beach, California
Pacific Clinical Studies
Los Alamitos, California
Wetlin Research Associates, Inc.
San Diego, California
Diablo Clinical Research, Inc.
Walnut Creek, California